Health Canada has completed a safety review which examined how patients respond when they are switched from one methadone-containing product to another for the treatment of opioid dependence. The review found that there may be a link between switching methadone-containing products and the risk of lack of effect which may present as withdrawal symptoms. Health Canada is informing healthcare professionals of this safety issue and will be updating the product information to warn of this safety issue. Products affected Brand/ Product Name Medicinal Ingredient and Strength DIN Manufacturer Jamp Methadone Oral Concentrate* methadone hydrochloride oral concentrate, 10 mg/mL 02495783 Jamp Pharma Corporation Metadol-D methadone hydrochloride oral solution, 1 mg/mL 02247374 Paladin Labs Inc. Metadol-D methadone hydrochloride oral concentrate, 10 mg/mL 02244290 Paladin Labs Inc. Methadose methadone hydrochloride oral concentrate, 10 mg/mL 02394618 Mallinckrodt Canada ULC Methadose methadone hydrochloride oral concentrate, 10 mg/mL 02394596 Mallinckrodt Canada ULC Odan-Methadone* methadone hydrochloride oral concentrate, 10 mg/mL 02495872 Odan Laboratories Ltd. Odan-Methadone* methadone hydrochloride oral concentrate, 10 mg/mL 02495880 Odan Laboratories Ltd. Sandoz Methadone methadone hydrochloride oral concentrate, 10 mg/mL 02481979 Sandoz Canada Inc. * Jamp Methadone Oral Concentrate and Odan-Methadone have been authorized for use in Canada since January 2020; as of the date of this communication, they are not marketed.
RecallTracker